Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Use of Pentosan Polysulfate to Treat Certain Conditions of the Prostate

Posted Jun 13 2010 5:00pm

Description of Invention:
Benign prostatic hyperplasia (BPH), involving a proliferation of smooth muscle cells and increased deposition of extracellular matrix, is a common development: 50% of men over age 60 (about 12.5 million men), and as much as 80% of all men over age 80 (about 3.2 million men), have some enlargement of the prostate gland.

This technology is a method for treating BHP using the oral medication, pentosan polysulfate. Pentosan polysulfate is a well known semi-synthetic polysaccharide extracted from beech wood cellulose that is FDA approved for the treatment of interstitial fibrosis. The current technology builds on the surprising discovery that pentosan polysulfate can cause regression of scarring and lesions in prostatic tissue. Pentosan polysulfate reduces or eliminates both smooth muscle cell proliferation and extracellular matrix deposition, and thus reduces the size of the prostate gland and associated obstructive symptoms.

Applications:
A method of treating benign prostatic hyperplasia using pentosan polysulfate.

Advantages:
  • The method treats the underlying pathology of BHP non-invasively.
  • The method addresses associated conditions, such as chronic prostatitis, prostadynia, and irritative bladder conditions (other than interstitial cystitis).
  • Pentosan polysulfate has been FDA approved for another use.


Development Status:
In vitro studies on BPH biopsy samples that demonstrate the drug slows the growth of prostate cells and extracellular matrix have been completed.

Inventors:
Gary E Striker (NIDDK)
Liliane J Striker (NIDDK)


Patent Status:
HHS, Reference No. E-104-1997/0
US, , Patent No. 6,828,309, Issued 07 Dec 2004
PCT, Application No. PCT/US01/01837 filed 19 Jan 2001


Relevant Publication:
  1. SJ Elliot et al. Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. Prostate Cancer Prostatic Dis. 2003;6(2):138-142. [ PubMed abs ]


Licensing Status:
Available for licensing.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Rare Diseases
In-vitro Data



For Additional Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220


Ref No: 1818

Updated: 06/2010

Post a comment
Write a comment:

Related Searches